炎症与癌症预后密切相关，非甾体抗炎药恰乌酮（Celecoxib）对癌症患者预后的影响仍不明确。为了评估Celecoxib联合标准化疗与癌症预后之间的关联性，我们进行了系统性的回顾和荟萃分析。在PubMed、EMBASE和Cochrane图书馆中搜寻从成立以来到2022年7月所有有关Celecoxib联合标准化疗治疗癌症患者的随机对照试验报道。主要终点是总生存期（OS）和无进展生存期（PFS）。荟萃分析使用Review Manager 5.4软件进行。在数据库中使用以下搜索词：((((Celecoxib)) AND ((((((((Cancer) OR (Carcinoma)) OR (Sarcoma)) OR (Neoplasms)) OR (Tumor)) OR (Tumour)) OR (Tumors)) OR (Tumours))) AND ((Survival) OR (Mortality))) AND (((Clinical Trials,Randmoized) OR (Trials, Randomized Clinical)) OR (Controlled Clinical Trials, Randomized))。 总体而言，本分析包括8957名癌症患者的13个随机对照试验。与常规化疗相比，Celecoxib的辅助治疗未显著改善1年OS和1年PFS率（OS：P= .38；PFS：P= .65）。此外，Celecoxib组和安慰剂组在3年总体（P= .98）、3年无进展（P= .40）、5年总体（P= .59）或5年无进展（P= .56）生存率没有差异。观察到白细胞减少症（P= .02）和血小板减少症（P= .05）的危险比增加，表明Celecoxib促进了血液学毒性。未观察到心血管（P= .96）和胃肠道反应（P= .10-0.91）风险增加。 Celecoxib联合标准化疗并没有改善癌症患者的OS或PFS率。此外，Celecoxib可能会增加血液学毒性，但不会增加胃肠道或心血管反应的风险。需要进一步的随机对照试验来澄清其作用和应用。©2023年欧洲临床研究学会杂志基金会。由John Wiley＆Sons Ltd.发布。

Inflammation is closely related to cancer prognosis. The effect of celecoxib, a nonsteroidal anti-inflammatory drug, on the prognosis of patients with cancer remains uncertain. To assess the association between celecoxib plus standard chemotherapy and cancer prognosis, we conducted a systematic review and meta-analysis of published studies.PubMed, EMBASE, and the Cochrane Library were searched from inception until July 2022 for randomized controlled trials reporting the prognosis of patients with cancer treated with celecoxib plus standard chemotherapy. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Meta-analysis was performed using Review Manager software version 5.4. The following search terms were used in the databases: ((((celecoxib)) AND ((((((((cancer) OR (carcinoma)) OR (sarcoma)) OR (neoplasms)) OR (tumor)) OR (tumour)) OR (tumors)) OR (tumours))) AND ((survival) OR (mortality))) AND (((Clinical Trials, Randomized) OR (Trials, Randomized Clinical)) OR (Controlled Clinical Trials, Randomized)).Overall, 13 randomized controlled trials, including 8957 patients with cancer, were included in the analysis. Compared to conventional chemotherapy alone, 1-year OS and 1-year PFS rates were not significantly improved with celecoxib adjuvant therapy (OS: p = .38; PFS: p = .65). In addition, no differences were observed between the celecoxib and placebo groups in 3-year overall (p = .98), 3-year progression-free (p = .40), 5-year overall (p = .59), or 5-year progression-free (p = .56) survival rates. An increase in the risk ratio of leukopenia (p = .02) and thrombocytopenia (p = .05) was also observed, suggesting that celecoxib promotes hematologic toxicity. No increased risk of cardiovascular (p = .96) and gastrointestinal (p = .10-.91) events was observed.The addition of celecoxib to standard chemotherapy did not improve OS or PFS rates of patients with cancer. Additionally, celecoxib can increase hematologic toxicity without increasing the risk of gastrointestinal or cardiovascular reactions. Further randomized controlled trials are necessary to clarify its effects and applications.© 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.